Skip to main content
Uncategorized

Ysios Capital Partners participates in the €30million financing of Endosense

By 29 de November de 2012November 18th, 2020No Comments
< Back to news
Ysios partners: Josep Ll. Sanfeliu, Julia Salaverria, Joël Jean Mairet and Cristina Garmendia. © Ysios.
 29.11.2012

Ysios Capital Partners participates in the €30million financing of Endosense

Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the close of a €30million Series C financing, making it one of the largest rounds of funding in medical technology to be held in Europe. Led by new investor NGN Capital, the round drew large participation from all existing investors, including Ysios Capital Partners. This Spanish venture capital firm –based in the Barcelona Science Park– has invested in a total of 9 healthcare and biotechnology companies, with special focus on pharmaceuticals and medical devices, through its first fund Ysios BioFund I of € 69 million.


Led by new investor NGN Capital, the round drew large participation from all existing investors, including Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie, as well as multiple employees. As part of the financing activity, NGN Capital Managing General Partner Peter Johann, Ph.D. has joined the Endosense board of directors.

Proceeds will be used to support the growth of a new direct sales organization in Europe; commercialization of the recently introduced third-generation TactiCath Quartz forcesensing catheter in the region; development of next generation products; completion of the TOCCASTAR investigational device exemption (IDE) clinical study follow-up and FDA approval submission for the TactiCath; and, the launch of the device in the United States.

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

Ysios Capital Partners manages Ysios BioFund I, –founded in 2008 with a total amount of €69 million– and has nine portfolio companies: MedLumics (Madrid), AM-Pharma BV (Bunnik, The Netherlands), STAT Diagnostica (Barcelona), Sabirmedical (Barcelona), Cardoz (Stockholm, Sweden), Endosense (Geneva), Biovex (now Amgen, Boston) and Cellerix (Madrid, now Tigenix NV NYSE Alternext:TIG).